• 主题
高级搜索  >
历史搜索 清空历史
首页> 外文期刊>Therapeutic advances in cardiovascular disease. >Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study
【24h】

Efficacy and safety of olmesartan/amlodipine/hydrochlorothiazide in patients with hypertension not at goal with mono, dual or triple drug therapy: results of the CHAMPiOn study

机译：奥美沙坦/氨氯地平/氢氯噻嗪对单药，双药或三药治疗未达到目标的高血压患者的疗效和安全性：CHAMPiOn研究的结果

获取原文
           
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

To assess the efficacy and safety of once daily olmesartan medoxomil (OM)/amlodipine besylate (AM)/hydrochlorothiazide (HCTZ) 40/10/25 mg in patients with hypertension not at goal with mono, dual or triple drug therapy. This was a single-center, prospective, open-label, blinded-endpoint study. After a 1-week screening visit, 40 patients were enrolled into the study and given once daily treatment with OM/AM/HCTZ after the patients underwent baseline ambulatory blood pressure monitoring (ABPM) on their original therapy. The primary endpoint was changes from baseline in mean 24 h ABPM [systolic blood pressure (SBP)] after the first day of therapy with OM/AM/HCTZ 40/10/25 mg. Secondary endpoints were changes from baseline in mean 24 h ABPM [diastolic blood pressure (DBP)] after the first day of therapy with OM/AM/HCTZ 40/10/25 mg; mean changes from baseline in trough seated SBP (SeSBP) at day 1 and SeSBP at weeks 1, 2, 3 and 4; mean changes from baseline in trough seated DBP (SeDBP) at day 1 and SeDBP at weeks 1, 2, 3 and 4; and the percentage of subjects achieving mean 24 h, daytime and night-time ABPM BP goals. The baseline paired t-test systolic ABPM was 134.0 ± 2.77 mmHg and day 1 was 128.6 ± 2.47 mmHg with a treatment difference of ?5.55 ± 1.3 mmHg (p t-test ABPM SBP reduction was 117.7 ± 2.0 mmHg with a treatment difference of ?16.5 ± 1.8 mmHg (p t-test ABPM SBP reduction was 115.8 ± 1.8 mmHg with a treatment difference of ?18.4 ± 2.0 mmHg (p t-test ABPM SBP reduction was 115.5 ± 1.9 mmHg with a treatment difference of ?18.6 ± 2.0 mmHg (p t-test ABPM SBP reduction was 115.5 ± 1.8 mmHg with a treatment difference of ?18.6 ± 2.2 mmHg (p t-test SeSBP was 142 ± 2.43 mmHg and day 1 was 132 ± 2.59 mmHg with a treatment difference of ?9.78 ± 1.51 mmHg (p t-test SeSBP reduction was 124.0 ± 1.6 mmHg with a treatment difference of ?17.9 ± 1.8 mmHg (p t-test SeSBP reduction was 120.3 ± 1.7 mmHg with a treatment difference of ?21.5 ± 2.1 mmHg (p t-test SeSBP reduction was 118.5 ± 1.8 mmHg with a treatment difference of ?23.3 ± 1.7 mmHg (p t-test SeSBP reduction was 119.6 ± 1.7 mmHg with a treatment difference of ?22.2 ± 1.9 mmHg (p Treatment with OM/AM/HCTZ achieved superior (SBP) ABPM reductions compared with mono, dual or triple drug therapy, resulting in all patients achieving systolic ABPM goal without ABPM documented hypotension.
机译：评估每日一次奥美沙坦美多西莫（OM）/苯磺酸氨氯地平（AM）/氢氯噻嗪（HCTZ）40/10/25 mg在非单药，双药或三药治疗目标患者中的疗效和安全性。这是一项单中心，前瞻性，开放标签，盲目的研究。经过1周的筛选访问后，有40名患者参加了研究，并在患者接受原始治疗的基线动态血压监测（ABPM）之后，每天接受OM / AM / HCTZ一次治疗。主要终点是用OM / AM / HCTZ 40/10/25 mg治疗第一天后，平均24小时ABPM [收缩压（SBP）]与基线相比的变化。次要终点是使用OM / AM / HCTZ 40/10/25 mg治疗的第一天后，平均24小时ABPM [舒张压（DBP）]与基线相比的变化;在第1天和第1、2、3和4周时，坐姿SBP（SeSBP）与基线的平均变化;第1天和第1、2、3和4周时，SeDBP的最低坐位DBP（SeDBP）相对于基线的平均变化;以及达到平均24小时，白天和夜间ABPM BP目标的受试者百分比。基线配对t检验收缩期ABPM为134.0±2.77 mmHg，第1天为128.6±2.47 mmHg，治疗差异为±5.55±1.3 mmHg（p t-test ABPM SBP降低为117.7±2.0 mmHg，治疗差异为？ 16.5±1.8 mmHg（p t-检验ABPM SBP降低为115.8±1.8 mmHg，治疗差异为±18.4±2.0 mmHg（p t-检验ABPM SBP降低为115.5±1.9 mmHg，治疗差异为±18.6±2.0 mmHg （p t-检验ABPM SBP降低为115.5±1.8 mmHg，治疗差异为±18.6±2.2 mmHg（p t-检验SeSBP为142±2.43 mmHg，第1天为132±2.59 mmHg，治疗差异为±9.78± 1.51 mmHg（p t-检验SeSBP降低为124.0±1.6 mmHg，治疗差异为±17.9±1.8 mmHg（p t-检验SeSBP降低为120.3±1.7 mmHg，治疗差异为±21.5±2.1 mmHg（p-试验SeSBP降低为118.5±1.8 mmHg，治疗差异为？23.3±1.7 mmHg（p t试验SeSBP降低为119.6±1.7 mmHg，治疗d σ22.2±1.9 mmHg（p）OM / AM / HCTZ治疗与单药，双药或三药治疗相比可实现出色的（SBP）ABPM降低，导致所有患者均达到收缩期ABPM目标，而无ABPM记录的低血压。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号